Fox Chase Cancer Center News

PHILADELPHIA (October 23, 2018) – John Michael Daly, MD, FACS, a surgical oncologist at Fox Chase Cancer Center, is among a group of 91 esteemed surgeons from seven countries selected to the new American College of Surgeons (ACS) Academy of Master Surgeon Educators™. 

PHILADELPHIA (October 22, 2018) – An analysis led by researchers at Fox Chase Cancer Center found that treating localized prostate cancer with hypofractionated intensity modulated radiation therapy (H-IMRT) yields equivalent disease outcomes compared with conventional intensity modulated radiation (C-IMRT).

PHILADELPHIA (October 21, 2018) – A new analysis of nearly 600 men who received brachytherapy for prostate cancer shows that overall incidence of complications related to the procedure within four months of treatment is less than 20 percent. All patients were treated at Fox Chase Cancer Center.

PHILADELPHIA (October 10, 2018)— Using a detailed analysis comparing the genetic and molecular makeup of tumors from nearly 1,000 patients with four common mouse models of hepatocellular carcinoma (HCC), researchers have identified animal models that most closely mimic human disease. 

PHILADELPHIA (October 4, 2018) – Jose Russo, MD, FACP, director of the Irma H. Russo, MD, Breast Cancer Research Lab at Fox Chase Cancer Center, named by AL DÍA as one of nine recipients of their Hispanic Heritage Award for 2018.

PHILADELPHIA (October 2, 2018) — Observing how cells of the intestinal epithelium respond to Salmonella, scientists at Fox Chase Cancer Center have found a novel mechanism of cell death that shows a way to control the spread of bacteria.

PHILADELPHIA (October 2, 2018) – Fox Chase Cancer Center will again field a team  to raise funds at the Pancreatic Cancer Action Network (PanCAN) PurpleStride Philadelphia. The event will be held on Saturday, November 3 at Memorial Hall in Fairmount Park.

PHILADELPHIA (October 1, 2018) – October is Breast Cancer Awareness month. Fox Chase Cancer Center reminds women to schedule their screening test for breast cancer—the most reliable way to detect breast cancer early, when the disease is most treatable.